Irinotecan (Camptosar): Uses, Side Effects, Interactions, Pictures, Warnings & Dosing

What Is Irinotecan?

Irinotecan hydrochloride is a cytotoxic chemotherapy drug in the topoisomerase I inhibitor class. It is also known as CPT-11. Camptosar is the best-known U.S. brand name, although generic irinotecan hydrochloride injections are widely available.

Irinotecan is a prodrug, meaning the body converts it into a more active substance called SN-38. This metabolite blocks topoisomerase I, an enzyme that helps unwind and repair DNA while cells divide. When the enzyme is trapped on DNA, damaging breaks accumulate. Rapidly dividing cancer cells may then stop growing or die.

Unfortunately, some healthy tissues also divide quickly. That explains why irinotecan can affect the bone marrow, digestive tract, hair follicles, and other normal cells. Chemotherapy is very good at disrupting a cancer cell’s plans, but it is not famous for being subtle.

Conventional Irinotecan Is Not the Same as Liposomal Irinotecan

This article focuses on conventional irinotecan, including Camptosar. Liposomal irinotecan, sold as Onivyde, is packaged inside lipid particles and has different FDA-approved uses, doses, and administration instructions. The two formulations are not automatically interchangeable.

What Is Irinotecan Used For?

FDA-Approved Uses

Camptosar is FDA-approved for metastatic cancer of the colon or rectum in two main situations:

• As part of first-line treatment with fluorouracil, commonly called 5-FU, and leucovorin.
• As treatment for metastatic colorectal cancer that has returned or progressed after earlier fluorouracil-based therapy.

Common Combination Regimens

Irinotecan is frequently included in combination chemotherapy because different drugs can attack cancer through different mechanisms. Examples include:

• FOLFIRI: irinotecan, leucovorin, and fluorouracil.
• FOLFIRI plus targeted therapy: a biologic drug such as bevacizumab, cetuximab, or panitumumab may be added when appropriate.
• FOLFIRINOX: irinotecan, oxaliplatin, leucovorin, and fluorouracil, used in selected pancreatic cancer settings.
• CAPIRI or XELIRI: irinotecan combined with capecitabine in selected gastrointestinal cancer regimens.

The precise combination depends on the cancer’s location, molecular test results, previous treatment, treatment goals, organ function, and the patient’s ability to tolerate intensive therapy.

Off-Label Uses

Oncologists may use conventional irinotecan off label for selected pancreatic, gastric, esophageal, lung, ovarian, cervical, sarcoma, brain, or pediatric solid tumors. An off-label use is not necessarily inappropriate; it means the specific use is not included in the product’s formal FDA-approved indication. Decisions should be based on clinical evidence, cancer guidelines, and individual circumstances.

What Does Irinotecan Look Like? Pictures and Identification

Camptosar is supplied as a sterile, clear, pale-yellow aqueous solution. The branded product contains 20 milligrams of irinotecan hydrochloride per milliliter and is available in single-dose vials such as:

• 40 mg in 2 mL
• 100 mg in 5 mL
• 300 mg in 15 mL

Generic vial sizes, carton colors, caps, labels, and protective containers may look different. Package photographs can therefore help illustrate the product but should not be used to confirm that a vial is correct. Oncology pharmacists verify the drug, concentration, dose, preparation, and patient information before the infusion.

The concentrated medicine is diluted into an intravenous solution before administration. Patients normally do not store, mix, or inject irinotecan at home.

How Is Irinotecan Given?

Irinotecan is administered into a vein, usually through a peripheral IV line or an implanted port. A conventional infusion often lasts about 90 minutes. Antinausea medication is generally given before treatment, and atropine may be provided when a patient has experienced early diarrhea or other acute cholinergic symptoms.

Before each cycle, the oncology team may review:

• Complete blood count, including neutrophils, hemoglobin, and platelets
• Liver function and bilirubin
• Kidney function and electrolyte levels
• Diarrhea, vomiting, infection, mouth sores, fatigue, and other toxicities
• Weight, body surface area, performance status, and current medications

A scheduled dose may be delayed or reduced when blood counts have not recovered, diarrhea remains active, or another significant toxicity is present. A delay is not a treatment failure. Sometimes it is simply the body requesting a maintenance daywith considerably less polite wording.

Irinotecan Dosing

Irinotecan doses are commonly calculated in milligrams per square meter of body surface area. The following are examples from U.S. Camptosar prescribing information, not instructions for self-treatment.

Modern cancer protocols may arrange the same medicine differently. For example, FOLFIRI commonly includes irinotecan every two weeks. The treating institution’s regimen takes priority over a general drug table.

Why the Starting Dose May Be Lower

A reduced dose may be considered for patients with previous abdominal or pelvic radiation, reduced performance status, elevated bilirubin, troublesome previous toxicity, or genetic variants that decrease UGT1A1 activity.

The U.S. label does not provide a recommended dose when bilirubin is above 2 mg/dL because available information is insufficient. Liver dysfunction can reduce irinotecan clearance and increase exposure to SN-38.

UGT1A1 Testing and Dose Adjustment

The UGT1A1 enzyme helps inactivate SN-38. People with two reduced-function alleles, such as UGT1A1*28/*28, *6/*6, or *6/*28, may have greater SN-38 exposure and a higher risk of severe or life-threatening neutropenia. Some may also face increased diarrhea risk.

The label recommends considering UGT1A1 genotype testing and reducing the starting dose by at least one level for known poor metabolizers. The exact reduction is not universal, so later doses are adjusted according to laboratory results and tolerance.

Irinotecan Side Effects

Common Side Effects

Not everyone develops every adverse effect, and severity can differ from one cycle to the next. Commonly reported irinotecan side effects include:

• Diarrhea or constipation
• Nausea and vomiting
• Abdominal pain or cramping
• Reduced appetite and weight loss
• Fatigue, weakness, or fever
• Low white blood cells, red blood cells, or platelets
• Hair thinning or hair loss
• Mouth sores
• Changes in liver laboratory results

Early Diarrhea and Cholinergic Syndrome

Early diarrhea occurs during the infusion or within approximately 24 hours afterward. It may appear with a runny nose, watery eyes, sweating, flushing, increased saliva, small pupils, intestinal cramping, or a slow heartbeat. This cluster is known as acute cholinergic syndrome.

Atropine can often prevent or relieve these symptoms when it is medically appropriate. Patients should report symptoms while they are still in the infusion center rather than quietly attempting to win a staring contest with the IV pole.

Late Diarrhea

Late diarrhea begins more than 24 hours after treatment and can become prolonged or life-threatening. Possible complications include dehydration, electrolyte imbalance, kidney injury, infection, colitis, bowel obstruction, bleeding, sepsis, and, rarely, intestinal perforation.

Patients are generally instructed to keep loperamide available and begin it at the first loose stool or increase above their normal bowel frequency. One regimen described in the Camptosar label begins with 4 mg, followed by 2 mg every two hours until the patient has been diarrhea-free for at least 12 hours. The label warns against continuing that intensive schedule for more than 48 consecutive hours because of the risk of paralytic ileus.

This high-intensity schedule must be used only according to the oncology team’s instructions. It is not the same as casually following the standard over-the-counter package directions. Contact the cancer team when diarrhea begins, and seek urgent help for blood or black stool, dizziness, faintness, inability to drink, fever, severe pain, reduced urination, or diarrhea that is not controlled within 24 hours.

Myelosuppression and Infection

Irinotecan can suppress the bone marrow, reducing neutrophils and other blood cells. Severe neutropenia can lead to febrile neutropenia, sepsis, hospitalization, treatment delays, and occasionally death.

Any fever, chills, shaking, sore throat, new cough, burning urination, worsening weakness, or other sign of infection should be reported immediately. Do not take acetaminophen simply to hide a fever before speaking with the oncology team.

Other Serious Reactions

Less common but potentially serious problems include severe allergic reactions, interstitial lung disease, acute kidney failure related to fluid loss, severe dehydration, bowel complications, and significant liver-related toxicity. New shortness of breath, cough, facial swelling, widespread rash, chest tightness, confusion, or very low urine output requires urgent evaluation.

Irinotecan Drug Interactions

Irinotecan is processed through pathways involving CYP3A4 and UGT1A1. Medicines or supplements that strongly alter these pathways can change exposure to irinotecan or SN-38.

Strong CYP3A4 Inducers

Strong inducers may lower drug exposure and potentially reduce effectiveness. Important examples include:

• Carbamazepine
• Phenytoin
• Phenobarbital
• Rifampin or rifabutin
• St. John’s wort

The prescribing information advises against combining strong CYP3A4 inducers with Camptosar unless no therapeutic alternative exists.

Strong CYP3A4 or UGT1A1 Inhibitors

Strong inhibitors may raise irinotecan or SN-38 exposure and increase toxicity. Examples include certain azole antifungals, macrolide antibiotics, HIV antivirals, and other medicines such as:

• Ketoconazole, itraconazole, or voriconazole
• Clarithromycin
• Ritonavir or related antiviral agents
• Atazanavir
• Gemfibrozil

Strong inhibitors may need to be discontinued or replaced before treatment, but only the prescribing clinicians should make that change.

Other Interaction Concerns

Laxatives and diuretics can worsen fluid loss during diarrhea. Other chemotherapy, radiation, or bone-marrow-suppressing medicines may add to low blood counts. Give the oncology pharmacist a complete list of prescriptions, nonprescription products, vitamins, traditional medicines, cannabis products, and herbal supplements. “Natural” does not mean “invisible to liver enzymes.”

Important Warnings and Precautions

• Pregnancy: Irinotecan can harm a developing fetus. Pregnancy status should be checked when appropriate before treatment.
• Contraception for females: Effective contraception is recommended during treatment and for six months after the final dose.
• Contraception for males: Men with partners who could become pregnant are advised to use condoms during treatment and for three months after the final dose.
• Breastfeeding: Breastfeeding is not recommended during treatment or for at least seven days after the final dose.
• Fertility: Treatment may impair fertility in females or males. Fertility preservation should ideally be discussed before therapy begins.
• Older adults: Patients older than 65 may require particularly close monitoring because diarrhea can be more frequent or severe.
• Kidney disease: Irinotecan should be used cautiously. Severe vomiting and diarrhea can cause dehydration and acute kidney injury.
• Liver disease: Reduced clearance may increase toxicity, especially when bilirubin is elevated.
• Lung disease: Preexisting lung problems, radiation, or other lung-toxic medicines may increase concern for pulmonary toxicity.
• Allergy: A history of hypersensitivity to irinotecan or an ingredient in the product is a contraindication.

When to Contact the Cancer Care Team Immediately

Patients should obtain individualized emergency instructions before the first infusion. In general, urgent contact is appropriate for:

• Any fever, chills, or suspected infection
• Diarrhea beginning after treatment, especially if frequent or persistent
• Black, bloody, or unusually painful bowel movements
• Inability to drink or repeated vomiting
• Dizziness, fainting, confusion, or very little urine
• New cough, breathing difficulty, or chest tightness
• Facial swelling, hives, or other signs of an allergic reaction
• Unusual bleeding, large bruises, or pinpoint red spots
• Severe weakness or a rapidly worsening overall condition

Experiences With Irinotecan: What Treatment May Feel Like in Daily Life

Experiences with irinotecan vary widely. The following discussion reflects commonly reported treatment patterns and practical lessons rather than one person’s medical story.

Infusion Day Often Begins With Waiting, Blood Tests, and Premedication

A typical appointment may begin with laboratory testing, a weight check, questions about bowel movements, and a review of symptoms since the previous cycle. Once the team confirms that treatment can proceed, the patient may receive antinausea medication before the irinotecan infusion. Someone with a history of cholinergic symptoms may also receive atropine.

During the approximately 90-minute infusion, some people feel little beyond tiredness or the inconvenience of being attached to equipment. Others notice abdominal cramping, sweating, watery eyes, nasal drainage, or an urgent need to use the restroom. Reporting those symptoms promptly allows the nurse to pause, assess, or provide medication. The infusion center is one place where oversharing about bowel habits is not awkward; it is excellent communication.

The Days After Treatment Can Develop a Predictable Rhythm

Some patients feel relatively well on infusion day because premedications are still working. Fatigue, appetite changes, nausea, or bowel symptoms may become more noticeable over the next several days. Late diarrhea may not begin immediately, which is why patients are often told to keep loperamide and the clinic’s phone number nearby even when they initially feel fine.

People sometimes learn that each cycle has a rhythm: treatment day, one or more difficult days, gradual improvement, and then a better period before the next infusion. Recording stool frequency, temperature, fluid intake, medications, and symptoms can help clinicians identify patterns and adjust supportive care.

Preparation Can Make Home Management Less Chaotic

Practical preparation may include stocking approved fluids, simple foods, a thermometer, skin-protection products, prescribed antinausea medicine, and the exact antidiarrheal instructions supplied by the clinic. Loose clothing, easy bathroom access, and help with meals or transportation can also be useful.

Hydration is often emphasized, but patients with heart, kidney, or electrolyte problems should follow individualized fluid advice. Sports drinks, broth, or oral rehydration products may be appropriate for some people, while others need a different plan. “Drink everything in sight” is not a medically precise hydration strategy.

Dose Delays and Reductions Are Common Safety Tools

A patient may feel discouraged when the oncologist delays treatment because neutrophils are low or diarrhea has not fully resolved. In practice, dose reductions and schedule changes are routine parts of cancer care. The goal is not to deliver the largest possible dose at any cost; it is to provide effective treatment while managing risk.

For example, someone receiving irinotecan every two weeks may tolerate the first cycle but develop significant diarrhea and neutropenia after the second. The team might delay the next dose, provide fluids, review UGT1A1 testing, strengthen supportive care, or reduce the irinotecan dose. That adjustment does not automatically mean the medicine has stopped working.

Hair, Appetite, and Energy Changes Can Affect More Than the Body

Hair thinning may be mild for one person and substantial for another. Reduced appetite, altered food preferences, fatigue, and repeated bathroom trips can also interrupt work, travel, sleep, and social plans. Patients may benefit from talking with an oncology dietitian, social worker, financial counselor, or mental health professional rather than trying to out-stubborn every problem alone.

Caregivers Often Become Part of the Safety System

A caregiver can help track medications, notice confusion or dehydration, monitor temperature, prepare fluids, and contact the treatment center when the patient is exhausted. It is helpful for both patient and caregiver to know which telephone number to use after hours and which symptoms require emergency care.

The most useful lesson reported across many irinotecan experiences is simple: call early. Severe diarrhea, infection, and dehydration are easier to manage before they turn into an overnight emergency. Oncology teams would rather answer a cautious question than meet a preventable crisis in the emergency department.

Conclusion

Irinotecan is an important topoisomerase I inhibitor used most prominently in metastatic colorectal cancer treatment. It may be administered alone or as part of combinations such as FOLFIRI, with dosing determined by body surface area, regimen, liver function, prior therapy, genetic factors, blood counts, and previous side effects.

Its two major safety concernssevere diarrhea and myelosuppressionmake education and rapid communication essential. Patients should understand the difference between early and late diarrhea, keep approved supportive medicines available, report fever immediately, and review every medication or supplement with the oncology team. With careful monitoring, dose adjustment, and prompt supportive care, many irinotecan-related problems can be managed more safely.

SEO Information